Oncology

Top news of the week in oncology and cancer drug development.

A patient discusses the struggle of receiving treatment for triple negative breast cancer in a rural community.

Major life events regarding close personal relationships may play a role in mortality.

Stivarga expanded to include the treatment of hepatocellular carcinoma in patients previously treated with sorafenib.

Stivarga is the first FDA-approved treatment for hepatocellular carcinoma in almost a decade.

The FDA has expanded the approved use of Stivarga (regorafenib, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.

Unexpected survival gains observed in glioblastoma patients administered an investigational dendritic cell vaccine and temozolomide.

The substantial adverse impact of second cancers may explain the lack of improvement in young adult survival compared with older adults.

Increased expression of EGFR-positive myeloid cells associated with tumor progression and reduced survival in bowel cancer.

Pharmacists and pharmacies have become key players in improving patient outcomes.

Redox active iron molecules react with vitamin C and increase cancer cell vulnerability.

Drug combination increases the efforts of killing cancer cells.

Top articles of the week from The American Journal of Pharmacy Benefits.

Top news of the week in oncology and cancer drug development.

Tool could improve detection of cancer, bacterial and viral infections.

Early detection found to improve survival in bowel cancer.

2D material nanopores are able to map DNA methylations.

Lung cancer screening rates among this high-risk population remained alarmingly low.

Findings could help improve treatment efficacy for patients with ALL.

Decline in cancer incidence rates most likely driven by modern antiretroviral therapies.

MicroRNA 506 triggers autophagy-related cell death in pancreatic cancer cells.

Hyper-sensitive test detects tumors earlier than current technology.

Protein determines whether breast cancer cells become resistant to tamoxifen.

Avella Specialty Pharmacy has issued its Outlook on Oncology report, a fact-based analysis that depicts the current state of the oncology industry and explores the trends, opportunities and new developments affecting cancer care delivery.

Protein determines whether breast cancer cells become resistant to tamoxifen.

Relapsing-remitting multiple sclerosis treatment found to trigger programmed cell death.

Atezolizumab is the first and only approved anti-PDL1 cancer immunotherapy.

Accelerated approval granted to atezolizumab (Tecentriq) for locally advanced or metastatic urothelial carcinoma in patients who are ineligible for cisplatin.